The Use of Autologous Platelet-Rich Plasma Gel in Urethral Stricture Disease Undergoing Buccal Mucosal Graft Urethroplasty: An Open-Labelled Parallel Randomized Controlled Trial

This is an open-labeled parallel randomized controlled trial evaluating the efficacy of autologous platelet-rich plasma (PRP) gel in preventing recurrence of urethral strictures in patients undergoing buccal mucosal graft urethroplasty (BMGU). Urethral stricture, a narrowing of the urethra due to fibrosis, is treated with BMGU for strictures longer than 3 cm, with success rates of 85-95%. PRP, rich in growth factors, is hypothesized to reduce fibrosis and enhance healing. The study compares conventional BMGU with BMGU plus PRP injection, involving 40 patients per group. Patients over 18 with urethral strictures are included, excluding those with thrombocytopenia, coagulation disorders, recurrent strictures, or unfit for surgery. Outcomes include the International Prostate Symptom Score (IPSS), perioperative complications, and stricture recurrence rates, assessed over six months with follow-ups at three-month intervals. PRP is prepared from 8-10 ml of autologous blood, processed through centrifugation. Data will be analyzed using SPSS, with statistical significance set at p<0.05. The study aims to improve BMGU outcomes by reducing fibrosis-related recurrence.